semaglutide compounding news november 2025 FDA's GLP-1 decision kicks off 'unprecedented' tussle over shortage Semaglutide injections will no longer

Beyond 48 hours, potency loss becomes measurable

However, this inhibitory effect is significantly weakened in patients with T2DM, indicating that its potential application in diabetes treatment requires further investigation

Retatrutide targets 3 hormone pathways vs Ozempics 1, achieving 24% weight loss in trials

Orforglipron represents the oral GLP-1 frontier, potentially eliminating the need for injections altogether

The result is a compound that simultaneously reduces caloric intake, improves insulin sensitivity, and accelerates fat oxidation

Researchers in clinical trials advised participants to limit alcohol intake